This extensive understanding emphasizes the multifaceted mechanisms of TKI resistance in CML, highlighting the necessity for targeted therapeutic approaches that address both BCR::ABL1 kinase-dependent and independent pathways to effectively overcome resistance. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.